September 30, 2024 09:00 AM EDT

Rivus details weight loss data in heart failure patients and preps for new fundraise

Max Bayer

Pharma Reporter

Rivus Pharmaceuticals’ obesity treatment for patients with heart failure spurred a 6.3-pound drop in weight compared to placebo after three months of treatment, said the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Rivus details weight loss data in heart failure patients and preps for new fundraise

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Vertex makes money from sickle cell therapy Casgevy

Sana narrows focus again to zero in on diabetes and autoimmune disease

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Rivus de­tails weight loss da­ta in heart fail­ure pa­tients and preps for new fundraise

Pharma Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Rivus details weight loss data in heart failure patients and preps for new fundraise